SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
50:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
for chemotherapy at some stage in their :@0.084242:0.096166:0.480482:0.096166:0.480482:0.080410:0.084242:0.080410:0.006042:0.012604:0.005792:0.007851:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007851:0.013143:0.006523:0.007851:0.007466:0.012604:0.018049:0.012508:0.007851:0.007466:0.006523:0.013143:0.012950:0.012508:0.007851:0.003848:0.011738:0.007851:0.006523:0.011738:0.012508:0.003848:0.005792:0.005330
treatment course.:@0.084242:0.112636:0.250645:0.112636:0.250645:0.096880:0.084242:0.096880:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012450:0.012604:0.011699:0.005792:0.007466:0.012508:0.005330
A  large meta-analysis  by the  Early :@0.102426:0.129106:0.480494:0.129106:0.480494:0.113350:0.102426:0.113350:0.014239:0.005330:0.011669:0.003848:0.013143:0.005813:0.012950:0.012508:0.017010:0.018049:0.012508:0.006523:0.013143:0.006388:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.005330:0.011694:0.013123:0.010314:0.017010:0.006523:0.011738:0.012508:0.005330:0.011669:0.010314:0.013143:0.005792:0.003848:0.010314:0.005330
Breast Trialist  Collaborative Group, which :@0.084242:0.145577:0.480474:0.145577:0.480474:0.129821:0.084242:0.129821:0.011045:0.005717:0.012508:0.013143:0.007466:0.006523:0.008524:0.007620:0.005792:0.003848:0.013143:0.003848:0.003848:0.007466:0.006523:0.005330:0.003206:0.015644:0.012604:0.003848:0.003848:0.013143:0.013123:0.012604:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.008524:0.016779:0.005713:0.012604:0.011699:0.013123:0.005330:0.008524:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330
included 4 756 patients from 10 clinical :@0.084242:0.162047:0.480451:0.162047:0.480451:0.146291:0.084242:0.146291:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.013181:0.010333:0.010660:0.010333:0.010660:0.010660:0.010672:0.010333:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010333:0.006042:0.005711:0.012604:0.018049:0.010333:0.010660:0.010660:0.010333:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330
trials, found an increased rate of breast :@0.084242:0.178517:0.480461:0.178517:0.480461:0.162761:0.084242:0.162761:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005330:0.009525:0.006042:0.012604:0.011699:0.011738:0.013181:0.009525:0.013143:0.011738:0.009525:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.009525:0.005792:0.013143:0.006523:0.012508:0.009525:0.012604:0.006042:0.009525:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
conservation among patients treated :@0.084242:0.194987:0.480495:0.194987:0.480495:0.179232:0.084242:0.179232:0.012450:0.012604:0.011738:0.007466:0.012508:0.005792:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.018800:0.013143:0.018049:0.012604:0.011738:0.012950:0.018800:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.018800:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330
with neoadjuvant chemotherapy (65%:@0.084242:0.211458:0.449500:0.211458:0.449500:0.195702:0.084242:0.195702:0.015990:0.003848:0.006523:0.011738:0.007505:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.007505:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005771:0.013143:0.013123:0.010314:0.007505:0.007100:0.010660:0.010660:0.014913
 vs :@0.449500:0.211458:0.480461:0.211458:0.480461:0.195702:0.449500:0.195702:0.007505:0.010660:0.007466:0.005330
49%). There  was no  difference  in  the  risk :@0.084242:0.227928:0.480490:0.227928:0.480490:0.212172:0.084242:0.212172:0.010660:0.010660:0.014913:0.007100:0.005330:0.008717:0.008197:0.011738:0.012508:0.005705:0.012508:0.005330:0.003373:0.015990:0.013143:0.007466:0.008717:0.011738:0.012604:0.005330:0.003369:0.013181:0.003848:0.006102:0.006042:0.012508:0.005709:0.012508:0.011738:0.012450:0.012508:0.005330:0.003369:0.003848:0.011738:0.005330:0.003377:0.006523:0.011738:0.012508:0.005330:0.003369:0.005792:0.003848:0.007466:0.009660:0.005330
of breast-cancer recurrence between :@0.084242:0.244398:0.480507:0.244398:0.480507:0.228642:0.084242:0.228642:0.012604:0.006042:0.017126:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.017126:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.017126:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.005330
the neoadjuvant group and the adjuvant :@0.084242:0.260869:0.480495:0.260869:0.480495:0.245113:0.084242:0.245113:0.006523:0.011738:0.012508:0.006081:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.006081:0.012950:0.005709:0.012604:0.011699:0.013123:0.006081:0.013143:0.011738:0.013181:0.006081:0.006523:0.011738:0.012508:0.006081:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330
chemotherapy  group (15-year rate  of :@0.084242:0.277339:0.480501:0.277339:0.480501:0.261583:0.084242:0.261583:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.009950:0.012950:0.005709:0.012604:0.011699:0.013123:0.015298:0.007100:0.010660:0.010660:0.006388:0.010314:0.012521:0.013143:0.005792:0.015298:0.005792:0.013143:0.006523:0.012508:0.005330:0.009958:0.012604:0.006042:0.005330
38.2%:@0.084242:0.293809:0.136466:0.293809:0.136466:0.278053:0.084242:0.278053:0.010660:0.010660:0.005330:0.010660:0.014913
 vs :@0.136466:0.293809:0.165041:0.293809:0.165041:0.278053:0.136466:0.278053:0.005118:0.010660:0.007466:0.005330
38%) and breast-cancer mortality :@0.164830:0.293809:0.480478:0.293809:0.480478:0.278053:0.164830:0.278053:0.010660:0.010660:0.014913:0.007100:0.005118:0.013143:0.011738:0.013181:0.005109:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005105:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330
(34.4% :@0.084242:0.310280:0.148897:0.310280:0.148897:0.294524:0.084242:0.294524:0.007100:0.010660:0.010660:0.005330:0.010660:0.014913:0.005330
versus:@0.148897:0.310280:0.204488:0.310280:0.204488:0.294524:0.148897:0.294524:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 33.7%) .:@0.204488:0.310280:0.280706:0.310303:0.280706:0.294547:0.204488:0.294524:0.005330:0.010660:0.010660:0.005330:0.010660:0.014913:0.007100:0.006234:0.750736
5:@0.269159:0.304684:0.275374:0.304684:0.275374:0.295499:0.269159:0.295499:0.006215
The choice of chemotherapy depends :@0.102426:0.326773:0.480491:0.326773:0.480491:0.311018:0.102426:0.311018:0.008197:0.011738:0.012508:0.007966:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.007966:0.012604:0.006042:0.007966:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007957:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.007466:0.005330
on patient factors and physician prefer-:@0.084242:0.343244:0.475151:0.343244:0.475151:0.327488:0.084242:0.327488:0.012604:0.011738:0.009467:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.009467:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.009467:0.013143:0.011738:0.013181:0.009467:0.013123:0.011738:0.010314:0.007466:0.003848:0.012450:0.003848:0.013143:0.011738:0.009467:0.013123:0.005715:0.012508:0.006042:0.012508:0.005792:0.006388
ences. The chemotherapy regimens used :@0.084242:0.359714:0.480493:0.359714:0.480493:0.343958:0.084242:0.343958:0.012508:0.011738:0.012450:0.012508:0.007466:0.005330:0.006589:0.008197:0.011738:0.012508:0.006583:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006585:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.006600:0.011699:0.007466:0.012508:0.013181:0.005330
in this setting are the same as those used :@0.084242:0.376184:0.480497:0.376184:0.480497:0.360428:0.084242:0.360428:0.003848:0.011738:0.006831:0.006523:0.011738:0.003848:0.007466:0.006831:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.006818:0.013143:0.005713:0.012508:0.006831:0.006523:0.011738:0.012508:0.006818:0.007466:0.013143:0.018049:0.012508:0.006831:0.013143:0.007466:0.006831:0.006523:0.011738:0.012604:0.007466:0.012508:0.006818:0.011699:0.007466:0.012508:0.013181:0.005330
in the adjuvant setting.:@0.084242:0.392655:0.297467:0.392655:0.297467:0.376899:0.084242:0.376899:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
These largely comprise anthracycline-:@0.102426:0.409125:0.475153:0.409125:0.475153:0.393369:0.102426:0.393369:0.008197:0.011738:0.012508:0.007466:0.012508:0.012142:0.003848:0.013143:0.005813:0.012950:0.012508:0.003848:0.010314:0.012142:0.012450:0.012604:0.018049:0.013123:0.005792:0.003848:0.007466:0.012508:0.012142:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.006388
containing:@0.084242:0.425595:0.184822:0.425595:0.184822:0.409839:0.084242:0.409839:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950
 vs :@0.184822:0.425595:0.216129:0.425595:0.216129:0.409839:0.184822:0.409839:0.007851:0.010660:0.007466:0.005330
non-anthracycline-contain-:@0.218650:0.425595:0.475157:0.425595:0.475157:0.409839:0.218650:0.409839:0.011738:0.012604:0.011738:0.006388:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012436:0.003848:0.003848:0.011738:0.012508:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.006388
ing regimens.:@0.084242:0.442066:0.208213:0.442066:0.208213:0.426310:0.084242:0.426310:0.003848:0.011738:0.012950:0.005330:0.005707:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330
The most common neoadjuvant chemo-:@0.102426:0.458536:0.475170:0.458536:0.475170:0.442780:0.102426:0.442780:0.008005:0.011545:0.012315:0.005292:0.017857:0.012411:0.007274:0.006331:0.005292:0.012257:0.012411:0.017857:0.017857:0.012411:0.011545:0.005292:0.011545:0.012315:0.012411:0.012950:0.012989:0.003714:0.011507:0.010468:0.012950:0.011545:0.006331:0.005292:0.012257:0.011545:0.012315:0.017857:0.012411:0.006388
therapy schedule in HER2-negative breast :@0.084242:0.475006:0.480472:0.475006:0.480472:0.459250:0.084242:0.459250:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.007245:0.007274:0.012257:0.011545:0.012315:0.012989:0.011507:0.003656:0.012315:0.007245:0.003656:0.011545:0.007243:0.012950:0.010122:0.011488:0.010468:0.006196:0.011545:0.012315:0.012758:0.012950:0.006331:0.003656:0.010468:0.012315:0.007243:0.012931:0.005521:0.012315:0.012950:0.007274:0.006519:0.005330
cancer  is  adriamycin,  cyclophosphamide :@0.084242:0.491477:0.480468:0.491477:0.480468:0.475721:0.084242:0.475721:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.005330:0.003010:0.003656:0.007274:0.005330:0.003011:0.012950:0.012989:0.005600:0.003656:0.012950:0.017857:0.010122:0.012257:0.003656:0.011545:0.005138:0.005330:0.003011:0.012257:0.010122:0.012257:0.003656:0.012411:0.012931:0.011545:0.012411:0.007274:0.012931:0.011545:0.012950:0.017857:0.003656:0.012989:0.012506:0.005330
3-weekly x 4, followed by weekly paclitaxel :@0.084242:0.507947:0.480447:0.507947:0.480447:0.492191:0.084242:0.492191:0.010468:0.006196:0.015798:0.012315:0.012315:0.009467:0.003656:0.010122:0.005022:0.009044:0.005022:0.010468:0.005138:0.005022:0.005850:0.012411:0.003656:0.003656:0.012411:0.015798:0.012315:0.012989:0.005022:0.012931:0.010122:0.005022:0.015798:0.012315:0.012315:0.009467:0.003656:0.010122:0.005022:0.012931:0.012950:0.012257:0.003656:0.003656:0.006331:0.012950:0.009044:0.012315:0.003852:0.005330
x 12 weeks, or 3-weekly docetaxel x 4.:@0.084242:0.524417:0.429951:0.524417:0.429951:0.508661:0.084242:0.508661:0.009044:0.005138:0.010468:0.010468:0.005138:0.015798:0.012315:0.012315:0.009467:0.007274:0.005138:0.005138:0.012411:0.005600:0.005138:0.010468:0.006196:0.015798:0.012315:0.012315:0.009467:0.003656:0.010122:0.005138:0.012989:0.012411:0.012257:0.012315:0.006331:0.012950:0.009044:0.012315:0.003656:0.005138:0.009044:0.005138:0.010468:0.005330
In patients who cannot tolerate an an-:@0.102426:0.540888:0.475151:0.540888:0.475151:0.525132:0.102426:0.525132:0.004349:0.011738:0.007274:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007274:0.015990:0.011738:0.012604:0.007274:0.012450:0.013143:0.011738:0.011738:0.012604:0.006523:0.007274:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.007274:0.013143:0.011738:0.007274:0.013143:0.011738:0.006388
thracycline,  TC (docetaxel,  cyclophos-:@0.084242:0.557358:0.475163:0.557358:0.475163:0.541602:0.084242:0.541602:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.005330:0.009993:0.008197:0.015644:0.015336:0.007100:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005330:0.009993:0.012450:0.010314:0.012450:0.003848:0.012604:0.013123:0.011738:0.012604:0.007466:0.006388
phamide)  administered 3-weekly  x 4 is  a :@0.084242:0.573828:0.480462:0.573828:0.480462:0.558072:0.084242:0.558072:0.013123:0.011738:0.013143:0.018049:0.003848:0.013181:0.012508:0.007100:0.005330:0.003052:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005719:0.012508:0.013181:0.008370:0.010660:0.006388:0.015990:0.012508:0.012508:0.009660:0.003848:0.010314:0.005330:0.003052:0.009236:0.008370:0.010660:0.008370:0.003848:0.007466:0.005330:0.003052:0.013143:0.005330
good alternative.:@0.084242:0.590298:0.246863:0.590298:0.246863:0.574543:0.084242:0.574543:0.012950:0.012604:0.012604:0.013181:0.005330:0.013143:0.003848:0.006523:0.012508:0.006181:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330
20-30% of cancers overexpress HER2 neu :@0.102426:0.606769:0.480489:0.606769:0.480489:0.591013:0.102426:0.591013:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.004676:0.012604:0.006042:0.004662:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.004666:0.012604:0.010660:0.012508:0.005709:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.004676:0.013143:0.010314:0.011680:0.010660:0.004676:0.011738:0.012508:0.011699:0.005330
protein. This makes the cancers more ag-:@0.084242:0.623239:0.475176:0.623239:0.475176:0.607483:0.084242:0.607483:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.006623:0.008197:0.011738:0.003848:0.007466:0.006639:0.018049:0.013143:0.009660:0.012508:0.007466:0.006639:0.006523:0.011738:0.012508:0.006627:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.006639:0.018049:0.012604:0.005709:0.012508:0.006639:0.013143:0.012950:0.006388
gressive,  with a higher propensity for dis-:@0.084242:0.639709:0.475139:0.639709:0.475139:0.623953:0.084242:0.623953:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330:0.005330:0.003073:0.015990:0.003848:0.006523:0.011738:0.008390:0.013143:0.008390:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.008390:0.013123:0.005715:0.012604:0.013123:0.012508:0.011738:0.007466:0.003848:0.006523:0.010314:0.008390:0.006042:0.012604:0.005792:0.008390:0.013181:0.003848:0.007466:0.006388
tant spread.:@0.084242:0.656180:0.197958:0.656180:0.197958:0.640424:0.084242:0.640424:0.006523:0.013143:0.011738:0.006523:0.005330:0.007466:0.013123:0.005709:0.012508:0.013143:0.013181:0.005330
The addition of trastuzumab to neoadju- :@0.102426:0.672650:0.480500:0.672650:0.480500:0.656894:0.102426:0.656894:0.008197:0.011738:0.012508:0.004791:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.004791:0.012604:0.006042:0.004791:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.004791:0.006523:0.012604:0.004791:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.006388:0.005330
vant  and subsequently  adjuvant  thera-:@0.084242:0.689120:0.475151:0.689120:0.475151:0.673364:0.084242:0.673364:0.010660:0.013143:0.011738:0.006523:0.005330:0.006841:0.013143:0.011738:0.013181:0.012180:0.007466:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.006837:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.006841:0.006523:0.011738:0.012508:0.005792:0.013137:0.006388
py increases  complete pathological re-:@0.084242:0.705591:0.475139:0.705591:0.475139:0.689835:0.084242:0.689835:0.013123:0.010314:0.011141:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330:0.005823:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.011141:0.013123:0.013143:0.006523:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.011141:0.005713:0.012508:0.006388
sponse rates,  which in turn have been :@0.084242:0.722061:0.480502:0.722061:0.480502:0.706305:0.084242:0.706305:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.011642:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.005330:0.006302:0.015990:0.011738:0.003848:0.012450:0.011738:0.011642:0.003848:0.011738:0.011642:0.006523:0.011699:0.006188:0.011738:0.011642:0.011738:0.013143:0.010660:0.012508:0.011642:0.013123:0.012508:0.012508:0.011738:0.005330
linked to a survival benefit in breast can-:@0.084242:0.738531:0.475151:0.738531:0.475151:0.722775:0.084242:0.722775:0.003848:0.003848:0.011738:0.009660:0.012508:0.013181:0.007601:0.006523:0.012604:0.007589:0.013143:0.007601:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007612:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.007585:0.003848:0.011738:0.007599:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.007599:0.012450:0.013143:0.011738:0.006388
cer.  The duration of trastuzumab is a total :@0.084242:0.755002:0.480477:0.755050:0.480477:0.739294:0.084242:0.739246:0.012450:0.012508:0.004376:0.005330:0.006215:0.005426:0.008197:0.011738:0.012508:0.005426:0.013181:0.011699:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005426:0.012604:0.006042:0.005426:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018038:0.013143:0.013123:0.005426:0.003848:0.007466:0.005426:0.013143:0.005426:0.006523:0.012604:0.006523:0.013143:0.003848:-0.095939
6:@0.118903:0.749431:0.125118:0.749431:0.125118:0.740246:0.118903:0.740246:0.006215
of one year.:@0.084249:0.771521:0.196061:0.771521:0.196061:0.755765:0.084249:0.755765:0.012604:0.006042:0.005330:0.012604:0.011738:0.012508:0.005330:0.010314:0.012508:0.013143:0.004362:0.005330
In 2013, the FDA approved pertuzumab, :@0.102433:0.787991:0.480489:0.787991:0.480489:0.772235:0.102433:0.772235:0.004349:0.011738:0.005357:0.010660:0.010660:0.010660:0.010660:0.005330:0.005359:0.006523:0.011738:0.012508:0.005351:0.009333:0.014316:0.014239:0.005355:0.013143:0.013123:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005359:0.013123:0.012508:0.005792:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.005330
an anti-HER2 monoclonal antibody that :@0.084249:0.804461:0.480489:0.804461:0.480489:0.788705:0.084249:0.788705:0.013143:0.011738:0.010891:0.013143:0.011738:0.006523:0.003848:0.006388:0.013143:0.010314:0.011680:0.010660:0.010891:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.010891:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.010891:0.006523:0.011738:0.013143:0.006523:0.005330
binds HER2/HER3 heterodimers,  which  is :@0.084249:0.820932:0.480475:0.820932:0.480475:0.805176:0.084249:0.805176:0.013123:0.003848:0.011738:0.013181:0.007466:0.011680:0.013143:0.010314:0.011680:0.010660:0.008409:0.013143:0.010314:0.011680:0.010660:0.011680:0.011738:0.012508:0.006523:0.012508:0.005703:0.012604:0.013181:0.003848:0.018049:0.012508:0.005792:0.007466:0.005330:0.005330:0.006338:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330:0.006340:0.003848:0.007466:0.005330
believed to be an important mechanism :@0.084249:0.837402:0.480487:0.837402:0.480487:0.821646:0.084249:0.821646:0.013123:0.012508:0.003848:0.003848:0.012508:0.010660:0.012508:0.013181:0.007755:0.006523:0.012604:0.007745:0.013123:0.012508:0.007755:0.013143:0.011738:0.007755:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.007743:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.005330
that is  responsible  for trastuzumab resist-:@0.084249:0.853872:0.475161:0.853872:0.475161:0.838116:0.084249:0.838116:0.006523:0.011738:0.013143:0.006523:0.009602:0.003848:0.007466:0.005330:0.004283:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.004285:0.006042:0.012604:0.005792:0.009602:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.009602:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.006388
ance. The combination of pertuzumab to :@0.084249:0.870343:0.480508:0.870343:0.480508:0.854587:0.084249:0.854587:0.013143:0.011738:0.012450:0.012508:0.005330:0.006408:0.008197:0.011738:0.012508:0.006408:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006408:0.012604:0.006042:0.006408:0.013123:0.012508:0.005792:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.006408:0.006523:0.012604:0.005330
trastuzumab and chemotherapy improves :@0.084249:0.886813:0.480473:0.886813:0.480473:0.871057:0.084249:0.871057:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.004349:0.013143:0.011738:0.013181:0.004349:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013123:0.013123:0.010314:0.004349:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.007466:0.005330
complete pathological response rates :@0.084249:0.903283:0.480487:0.903283:0.480487:0.887527:0.084249:0.887527:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.016972:0.013123:0.013143:0.006523:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.016972:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.016972:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330
compared  to  trastuzumab  and  chemo-:@0.084249:0.919753:0.475159:0.919753:0.475159:0.903998:0.084249:0.903998:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005330:0.005642:0.006523:0.012604:0.005330:0.005638:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.005638:0.013143:0.011738:0.013181:0.005330:0.005642:0.012450:0.011738:0.012508:0.018049:0.012598:0.006388
therapy alone.:@0.084249:0.936224:0.221890:0.936224:0.221890:0.920468:0.084249:0.920468:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330
7:@0.221870:0.930625:0.228085:0.930625:0.228085:0.921439:0.221870:0.921439:0.006215
ADJUVANT CHEMOTHERAPY:@0.523636:0.096122:0.807568:0.096122:0.807568:0.078306:0.523636:0.078306:0.015822:0.014966:0.010263:0.013683:0.014966:0.015822:0.015822:0.008980:0.005987:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
Adjuvant chemotherapy is chemotherapy :@0.523636:0.113690:0.919900:0.113690:0.919900:0.097934:0.523636:0.097934:0.014239:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.004522:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004508:0.003848:0.007466:0.004522:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
administered  following  definitive  surgery :@0.523636:0.130107:0.919891:0.130107:0.919891:0.114351:0.523636:0.114351:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005719:0.012508:0.013181:0.005330:0.006340:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.006338:0.013181:0.012508:0.004686:0.004686:0.011738:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330:0.006346:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.005330
for breast cancer, with the aim of reducing :@0.523636:0.146525:0.919895:0.146525:0.919895:0.130769:0.523636:0.130769:0.006042:0.012604:0.005792:0.004276:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.004291:0.012450:0.013143:0.011738:0.012450:0.012508:0.003766:0.005330:0.004281:0.015990:0.003848:0.006523:0.011738:0.004291:0.006523:0.011738:0.012508:0.004278:0.013143:0.003848:0.018049:0.004291:0.012604:0.006042:0.004280:0.005713:0.012508:0.013181:0.011699:0.012450:0.003848:0.011738:0.012950:0.005330
the risk of local and distant breast-cancer :@0.523636:0.162942:0.919893:0.162942:0.919893:0.147186:0.523636:0.147186:0.006523:0.011738:0.012508:0.005896:0.005792:0.003848:0.007466:0.009660:0.005907:0.012604:0.006042:0.005898:0.003848:0.012604:0.012450:0.013143:0.003848:0.005907:0.013143:0.011738:0.013181:0.005907:0.013181:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005907:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
recurrence.:@0.523636:0.179359:0.632034:0.179359:0.632034:0.163603:0.523636:0.163603:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.005330
The indications for adjuvant chemother-:@0.541820:0.195777:0.914545:0.195777:0.914545:0.180021:0.541820:0.180021:0.008197:0.011738:0.012508:0.005290:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005299:0.006042:0.012604:0.005792:0.005290:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005311:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005769:0.006388
apy have shifted from  the  use of  clinic-:@0.523636:0.212194:0.914547:0.212194:0.914547:0.196438:0.523636:0.196438:0.013143:0.013123:0.010314:0.009563:0.011738:0.013143:0.010660:0.012508:0.009563:0.007466:0.011738:0.003848:0.006042:0.006523:0.012508:0.013181:0.009563:0.006042:0.005711:0.012604:0.018049:0.005330:0.004224:0.006523:0.011738:0.012508:0.005330:0.004220:0.011699:0.007466:0.012508:0.009563:0.012604:0.006042:0.005330:0.004224:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.006388
pathological factors to genomic profiling :@0.523636:0.228612:0.919881:0.228612:0.919881:0.212856:0.523636:0.212856:0.013123:0.013143:0.006523:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.007657:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.007649:0.006523:0.012604:0.007649:0.012950:0.012508:0.011738:0.012592:0.018049:0.003848:0.012450:0.007658:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.003848:0.011738:0.012950:0.005330
of an individual cancer.:@0.523636:0.245029:0.744146:0.245029:0.744146:0.229273:0.523636:0.229273:0.012604:0.006042:0.005330:0.013143:0.011738:0.005330:0.003848:0.011738:0.013181:0.003848:0.010660:0.003848:0.013181:0.011699:0.013143:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004380:0.005330
8:@0.744144:0.239444:0.750358:0.239444:0.750358:0.230259:0.744144:0.230259:0.006215
The  traditional indications for  chemo-:@0.541818:0.261485:0.914543:0.261485:0.914543:0.245729:0.541818:0.245729:0.008197:0.011738:0.012508:0.005330:0.006548:0.006523:0.005792:0.013143:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.011892:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.011892:0.006042:0.012604:0.005792:0.005330:0.006548:0.012450:0.011738:0.012508:0.018049:0.012592:0.006388
therapy  were  tumour  size of  more  than :@0.523634:0.277902:0.919889:0.277902:0.919889:0.262146:0.523634:0.262146:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005009:0.015990:0.012508:0.005711:0.012508:0.005330:0.005013:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.004997:0.007466:0.003848:0.008178:0.012508:0.010352:0.012604:0.006042:0.005330:0.005013:0.018049:0.012604:0.005707:0.012508:0.005330:0.005011:0.006523:0.011738:0.013143:0.011738:0.005330
2 cm, positive axillary nodes, triple-nega-:@0.523634:0.294320:0.914537:0.294320:0.914537:0.278564:0.523634:0.278564:0.010660:0.007812:0.012450:0.018049:0.005330:0.007812:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.007812:0.013143:0.009236:0.003848:0.003848:0.003848:0.013143:0.005792:0.010314:0.007826:0.011738:0.012604:0.013181:0.012508:0.007466:0.005330:0.007812:0.006523:0.005792:0.003848:0.013123:0.003848:0.012508:0.006388:0.011738:0.012508:0.012950:0.013143:0.006388
tive breast cancer, HER2-positive breast :@0.523634:0.310737:0.919864:0.310737:0.919864:0.294981:0.523634:0.294981:0.006523:0.003848:0.010660:0.012508:0.011565:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.011565:0.012450:0.013143:0.011738:0.012450:0.012508:0.003762:0.005330:0.011565:0.013143:0.010314:0.011680:0.010660:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.011565:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
cancer, the  presence  of  lymphovascular :@0.523634:0.327154:0.919869:0.327154:0.919869:0.311399:0.523634:0.311399:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.008563:0.006523:0.011738:0.012508:0.005330:0.003219:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.003221:0.012604:0.006042:0.005330:0.003223:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330
invasion, and young age.:@0.523634:0.343572:0.761296:0.343572:0.761296:0.327816:0.523634:0.327816:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.012604:0.011738:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.010314:0.012604:0.011699:0.011738:0.012950:0.005330:0.013143:0.012950:0.012508:0.005330
Recently, however, a number  of :@0.541818:0.359989:0.919900:0.359989:0.919900:0.344233:0.541818:0.344233:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.024015:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.003770:0.005330:0.024015:0.013143:0.024015:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330:0.018675:0.012604:0.006042:0.005330
genomic profiling tests have received FDA :@0.523634:0.376407:0.919879:0.376407:0.919879:0.360651:0.523634:0.360651:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.004747:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.003848:0.011738:0.012950:0.004751:0.006523:0.012508:0.007466:0.006523:0.007466:0.004757:0.011738:0.013143:0.010660:0.012508:0.004757:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.004761:0.009333:0.014316:0.014239:0.005330
approval,  and  these  quantify  the  risk  of :@0.523634:0.392824:0.919877:0.392824:0.919877:0.377068:0.523634:0.377068:0.013143:0.013123:0.013123:0.005719:0.012604:0.010660:0.013143:0.003848:0.005330:0.005330:0.004474:0.013143:0.011738:0.013181:0.005330:0.004472:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.004466:0.013123:0.011699:0.013143:0.011738:0.006523:0.003848:0.006042:0.010314:0.005330:0.004474:0.006523:0.011738:0.012508:0.005330:0.004464:0.005792:0.003848:0.007466:0.009660:0.005330:0.004474:0.012604:0.006042:0.005330
breast-cancer recurrence with or without :@0.523634:0.409241:0.919879:0.409241:0.919879:0.393486:0.523634:0.393486:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007370:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.007370:0.015990:0.003848:0.006523:0.011738:0.007370:0.012604:0.005792:0.007370:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.005330
chemotherapy. In South Africa, two tests, :@0.523634:0.425659:0.919887:0.425659:0.919887:0.409903:0.523634:0.409903:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.007008:0.004349:0.011738:0.007023:0.009583:0.012604:0.011699:0.006523:0.011738:0.007014:0.014239:0.006042:0.005792:0.003848:0.012450:0.013143:0.005330:0.007023:0.006523:0.015990:0.012604:0.007023:0.006523:0.012508:0.007466:0.006523:0.007466:0.005330:0.005330
namely the  Oncotype  DX test and the :@0.523634:0.442076:0.919904:0.442076:0.919904:0.426320:0.523634:0.426320:0.011738:0.013143:0.018049:0.012508:0.003848:0.010314:0.011122:0.006523:0.011738:0.012508:0.005330:0.005778:0.016722:0.011738:0.012450:0.012604:0.006523:0.010314:0.013123:0.012508:0.005330:0.005778:0.014316:0.011719:0.011122:0.006523:0.012508:0.007466:0.006523:0.011122:0.013143:0.011738:0.013181:0.011122:0.006523:0.011738:0.012508:0.005330
Mammaprint tests, are in use. The tests are :@0.523634:0.458494:0.919890:0.458494:0.919890:0.442738:0.523634:0.442738:0.017684:0.013143:0.018049:0.018049:0.013143:0.013123:0.005792:0.003848:0.011738:0.006523:0.005109:0.006523:0.012508:0.007466:0.006523:0.007466:0.005330:0.005107:0.013143:0.005715:0.012508:0.005109:0.003848:0.011738:0.005118:0.011699:0.007466:0.012508:0.005330:0.005107:0.008197:0.011738:0.012508:0.005101:0.006523:0.012508:0.007466:0.006523:0.007466:0.005118:0.013143:0.005715:0.012508:0.005330
reported as a risk group (low-risk, interme-:@0.523634:0.474911:0.914555:0.474911:0.914555:0.459155:0.523634:0.459155:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.006063:0.013143:0.007466:0.006081:0.013143:0.006081:0.005792:0.003848:0.007466:0.009660:0.006081:0.012950:0.005709:0.012604:0.011699:0.013123:0.006071:0.007100:0.003848:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660:0.005330:0.006081:0.003848:0.011738:0.006523:0.012508:0.006319:0.018049:0.012508:0.006388
diate-risk or high-risk for Oncotype DX, or :@0.523634:0.491328:0.919867:0.491328:0.919867:0.475572:0.523634:0.475572:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005792:0.003848:0.007466:0.009660:0.007768:0.012604:0.005792:0.007755:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.007755:0.006042:0.012604:0.005792:0.007755:0.016722:0.011738:0.012450:0.012604:0.006523:0.010314:0.013123:0.012508:0.007755:0.014316:0.011719:0.005330:0.007755:0.012604:0.005792:0.005330
low-risk:@0.523634:0.507746:0.589231:0.507746:0.589231:0.491990:0.523634:0.491990:0.003848:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660
 vs :@0.589231:0.507746:0.618018:0.507746:0.618018:0.491990:0.589231:0.491990:0.005330:0.010660:0.007466:0.005330
high-risk for Mammaprint.):@0.618018:0.507746:0.860068:0.507746:0.860068:0.491990:0.618018:0.491990:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.005330:0.006042:0.012604:0.005792:0.005330:0.017684:0.013143:0.018049:0.018049:0.013143:0.013123:0.005792:0.003848:0.011738:0.006523:0.005330:0.007100
The low-risk group patients do not attain :@0.541818:0.524163:0.919879:0.524163:0.919879:0.508407:0.541818:0.508407:0.008197:0.011738:0.012508:0.005355:0.003848:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660:0.005369:0.012950:0.005709:0.012604:0.011699:0.013123:0.005359:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005369:0.013181:0.012604:0.005359:0.011738:0.012604:0.006523:0.005355:0.013143:0.006523:0.006523:0.013143:0.003848:0.011738:0.005330
a  benefit  from  chemotherapy,  and  the :@0.523634:0.540581:0.919887:0.540581:0.919887:0.524825:0.523634:0.524825:0.013143:0.005330:0.005667:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.005659:0.006042:0.005711:0.012604:0.018049:0.005330:0.005665:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013106:0.010314:0.005330:0.005330:0.005665:0.013143:0.011738:0.013181:0.005330:0.005665:0.006523:0.011738:0.012508:0.005330
high-risk group are managed with chemo-:@0.523634:0.556998:0.914543:0.556998:0.914543:0.541242:0.523634:0.541242:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.004695:0.012950:0.005709:0.012604:0.011699:0.013123:0.004695:0.013143:0.005713:0.012508:0.004695:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.013181:0.004695:0.015990:0.003848:0.006523:0.011738:0.004695:0.012450:0.011738:0.012508:0.018049:0.012611:0.006388
therapy. An ongoing clinical trial is under-:@0.523634:0.573415:0.914543:0.573415:0.914543:0.557659:0.523634:0.557659:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006177:0.014239:0.011738:0.006177:0.012604:0.011738:0.012950:0.012604:0.003848:0.011738:0.012950:0.006177:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.006196:0.006523:0.005792:0.003848:0.013143:0.003848:0.006188:0.003848:0.007466:0.006190:0.011699:0.011738:0.013181:0.012508:0.005767:0.006388
way  to  assess  the  benefit  of  chemother-:@0.523634:0.589833:0.914543:0.589833:0.914543:0.574077:0.523634:0.574077:0.015990:0.013143:0.010314:0.005330:0.003237:0.006523:0.012604:0.005330:0.003225:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.005330:0.003244:0.006523:0.011738:0.012508:0.005330:0.003225:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.003219:0.012604:0.006042:0.005330:0.003227:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005773:0.006388
apy in the intermediate-risk group where :@0.523634:0.606250:0.919894:0.606250:0.919894:0.590494:0.523634:0.590494:0.013143:0.013123:0.010314:0.007928:0.003848:0.011738:0.007918:0.006523:0.011738:0.012508:0.007912:0.003848:0.011738:0.006523:0.012508:0.006323:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005792:0.003848:0.007466:0.009660:0.007928:0.012950:0.005711:0.012604:0.011699:0.013123:0.007914:0.015990:0.011738:0.012508:0.005709:0.012508:0.005330
Oncotype Dx test is used. (TailoR ):@0.523634:0.622668:0.842174:0.622762:0.842174:0.607006:0.523634:0.606912:0.016722:0.011738:0.012450:0.012604:0.006523:0.010314:0.013123:0.012508:0.005330:0.014316:0.009236:0.005330:0.006523:0.012508:0.007466:0.006523:0.005330:0.003848:0.007466:0.005330:0.011699:0.007466:0.012508:0.013181:0.005330:0.005330:0.007100:0.007187:0.013143:0.003848:0.003848:0.012604:0.011680:0.011326:-0.263447
x :@0.823753:0.626518:0.835077:0.626518:0.835077:0.614270:0.823753:0.614270:0.007180:0.004143
The  tests  are  indicated  in  endocrine-:@0.541820:0.639179:0.914562:0.639179:0.914562:0.623423:0.541820:0.623423:0.008005:0.011545:0.012315:0.005330:0.007801:0.006331:0.012315:0.007274:0.006331:0.007274:0.005330:0.007801:0.012950:0.005521:0.012315:0.005330:0.007801:0.003656:0.011545:0.012989:0.003656:0.012257:0.012950:0.006331:0.012315:0.012989:0.005330:0.007801:0.003656:0.011545:0.005330:0.007801:0.012315:0.011545:0.012989:0.012411:0.012257:0.005600:0.003656:0.011545:0.012315:0.006388
responsive,  HER2-negative  breast  cancer, :@0.523636:0.655597:0.919862:0.655597:0.919862:0.639841:0.523636:0.639841:0.005521:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.003656:0.010468:0.012315:0.005138:0.005330:0.004316:0.012950:0.010122:0.011488:0.010468:0.006196:0.011545:0.012315:0.012758:0.012950:0.006331:0.003656:0.010468:0.012315:0.005330:0.004316:0.012931:0.005519:0.012315:0.012950:0.007274:0.006331:0.005330:0.004318:0.012257:0.012950:0.011545:0.012257:0.012315:0.003575:0.005326:0.005330
including patients with 1-3 positive axillary :@0.523636:0.672014:0.919877:0.672014:0.919877:0.656258:0.523636:0.656258:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012758:0.007735:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.007735:0.015798:0.003656:0.006331:0.011545:0.007735:0.010468:0.006196:0.010468:0.007735:0.012931:0.012411:0.007274:0.003656:0.006331:0.003656:0.010468:0.012315:0.007735:0.012950:0.009044:0.003656:0.003656:0.003656:0.012950:0.005600:0.010316:0.005330
nodes, and assist the clinician with decision-:@0.523636:0.688431:0.914564:0.688431:0.914564:0.672675:0.523636:0.672675:0.011545:0.012411:0.012989:0.012315:0.007274:0.005138:0.003637:0.012950:0.011545:0.012989:0.003637:0.012950:0.007274:0.007274:0.003656:0.007274:0.006331:0.003637:0.006331:0.011545:0.012315:0.003637:0.012257:0.003656:0.003656:0.011545:0.003656:0.012257:0.003656:0.012950:0.011545:0.003637:0.015798:0.003656:0.006331:0.011545:0.003637:0.012989:0.012315:0.012257:0.003656:0.007274:0.003656:0.012411:0.011545:0.006388
making pertaining to the additional benefit :@0.523636:0.704849:0.919891:0.704849:0.919891:0.689093:0.523636:0.689093:0.017857:0.012950:0.009467:0.003656:0.011545:0.012758:0.004507:0.012931:0.012315:0.005600:0.006331:0.012950:0.003656:0.011545:0.003656:0.011545:0.012758:0.004507:0.006331:0.012411:0.004507:0.006331:0.011545:0.012315:0.004507:0.012950:0.012989:0.012989:0.003656:0.006331:0.003656:0.012411:0.011545:0.012950:0.003656:0.004507:0.012931:0.012315:0.011545:0.012315:0.004589:0.004589:0.006519:0.005330
of chemotherapy in addition to hormone :@0.523636:0.721266:0.919923:0.721266:0.919923:0.705510:0.523636:0.705510:0.012411:0.005850:0.007928:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.007928:0.003656:0.011545:0.007928:0.012950:0.012989:0.012989:0.003656:0.006331:0.003656:0.012411:0.011545:0.007928:0.006331:0.012411:0.007928:0.011545:0.012411:0.006131:0.017857:0.012411:0.011545:0.012506:0.005330
blockade in patients who have undergone :@0.523636:0.737684:0.919889:0.737684:0.919889:0.721928:0.523636:0.721928:0.012931:0.003656:0.012411:0.012257:0.009467:0.012950:0.012989:0.012315:0.004637:0.003656:0.011545:0.004637:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.004637:0.015798:0.011545:0.012411:0.004637:0.011545:0.012950:0.010468:0.012315:0.004637:0.011507:0.011545:0.012989:0.012315:0.005615:0.012758:0.012411:0.011545:0.012506:0.005330
definitive surgery for breast cancer.:@0.523636:0.754101:0.843850:0.754101:0.843850:0.738345:0.523636:0.738345:0.012989:0.012315:0.004589:0.004589:0.011545:0.003656:0.006331:0.003656:0.010468:0.012315:0.005138:0.007274:0.011507:0.005613:0.012758:0.012315:0.005600:0.010122:0.005138:0.005850:0.012411:0.005600:0.005138:0.012931:0.005521:0.012315:0.012950:0.007274:0.006331:0.005138:0.012257:0.012950:0.011545:0.012257:0.012315:0.004185:0.005330
This has challenged the traditional in-:@0.541820:0.770518:0.914526:0.770518:0.914526:0.754762:0.541820:0.754762:0.008197:0.011738:0.003848:0.007466:0.010853:0.011738:0.013143:0.007466:0.010853:0.012450:0.011738:0.013143:0.003848:0.003848:0.012508:0.011738:0.012950:0.012508:0.013181:0.010853:0.006523:0.011738:0.012508:0.010853:0.006523:0.005792:0.013143:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.010853:0.003848:0.011738:0.006388
dications for  chemotherapy,  sparing pa-:@0.523636:0.786936:0.914545:0.786936:0.914545:0.771180:0.523636:0.771180:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.008794:0.006042:0.012604:0.005792:0.005330:0.003448:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003441:0.007466:0.013123:0.013143:0.005792:0.003848:0.011738:0.012950:0.008794:0.013123:0.013143:0.006388
tients from the short- and long-term effects :@0.523636:0.803353:0.919906:0.803353:0.919906:0.787597:0.523636:0.787597:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004349:0.006042:0.005713:0.012604:0.018049:0.004349:0.006523:0.011738:0.012508:0.004337:0.007466:0.011738:0.012604:0.005792:0.006523:0.006388:0.004331:0.013143:0.011738:0.013181:0.004349:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006319:0.018049:0.004349:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330
of chemotherapy. Clinical trials have indi-:@0.523636:0.819771:0.914539:0.819771:0.914539:0.804015:0.523636:0.804015:0.012604:0.006042:0.006081:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013123:0.013123:0.010314:0.005330:0.006081:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.006094:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.006081:0.011738:0.013143:0.010660:0.012508:0.006081:0.003848:0.011738:0.013181:0.003848:0.006388
cated  that  the  use  of  genomic  profiling :@0.523636:0.836188:0.919893:0.836188:0.919893:0.820432:0.523636:0.820432:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.004131:0.006523:0.011738:0.013143:0.006523:0.005330:0.004131:0.006523:0.011738:0.012508:0.005330:0.004133:0.011699:0.007466:0.012508:0.005330:0.004133:0.012604:0.006042:0.005330:0.004127:0.012950:0.012508:0.011738:0.012592:0.018049:0.003848:0.012450:0.005330:0.004137:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.003848:0.011738:0.012950:0.005330
changes clinician opinion in approximate-:@0.523636:0.852605:0.914535:0.852605:0.914535:0.836849:0.523636:0.836849:0.012450:0.011738:0.013143:0.011738:0.012950:0.012508:0.007466:0.004872:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.003848:0.013143:0.011738:0.004876:0.012604:0.013123:0.003848:0.011738:0.003848:0.012604:0.011738:0.004874:0.003848:0.011738:0.004876:0.013143:0.013123:0.013123:0.005719:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.006388
ly 25%-30% of cases.:@0.523636:0.869023:0.709652:0.869023:0.709652:0.853267:0.523636:0.853267:0.003848:0.010314:0.005330:0.010660:0.010660:0.014913:0.006388:0.010660:0.010660:0.014913:0.005330:0.012604:0.006042:0.005330:0.012450:0.013143:0.007466:0.012508:0.007466:0.005330
HORMONAL BLOCKADE:@0.523636:0.902254:0.764380:0.902254:0.764380:0.884439:0.523636:0.884439:0.014539:0.017960:0.012401:0.019242:0.017960:0.015822:0.015822:0.009407:0.005987:0.012401:0.009407:0.017960:0.016677:0.013256:0.015822:0.014966:0.011118
Patients  whose cancers  are hormone-:@0.523636:0.919822:0.914570:0.919822:0.914570:0.904066:0.523636:0.904066:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.009323:0.015990:0.011738:0.012604:0.007466:0.012508:0.014663:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.009323:0.013143:0.005715:0.012508:0.014663:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.012508:0.006388
responsive are  candidates for  adjuvant :@0.523636:0.936240:0.919879:0.936240:0.919879:0.920484:0.523636:0.920484:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.010660:0.012508:0.011584:0.013143:0.005713:0.012508:0.005330:0.006242:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.011584:0.006042:0.012604:0.005792:0.005330:0.006235:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330